Disease-associated vision changes are common in GCA, with no significant difference in visual improvement observed with IV glucocorticoids vs oral therapy.
Topline data were announced from a phase 3 trial evaluating secukinumab in patients with polymyalgia rheumatica.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback